Fundraising FoxMyris Therapeutics
Sharpsburg, US · Founded 2022 · Delaware corporation
Find your way into Myris Therapeutics
Sign up to see every warm intro you have to Myris Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Myris Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Myris Therapeutics applies polymer chemistry to develop next-generation medicines, with a flagship platform of ultra-high DAR antibody drug conjugates (ADCs). Its technology uses ATRP "growing from" methods to build polymer bottlebrushes that carry payloads, aimed at targeted cancer therapies across oncogenic pathways.
Founders & leadership
Myris Therapeutics was founded in 2022 by Krzysztof Matyjaszewski.
KM
Krzysztof MatyjaszewskiFounder
JP
Jean PineaultNamed on SEC filing
DC
David ColaizziNamed on SEC filing
AS
Antonina SimakovaNamed on SEC filing
PB
Patrick BaileyNamed on SEC filing
AG
Autumn GindlesbergerNamed on SEC filing
LE
Laura E. BenjaminNamed on SEC filing
RW
Rebecca WolfeNamed on SEC filing
BS
Barbara S. FoxNamed on SEC filing
MA
Mark A. MurckoNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$2M disclosed across 2 rounds · 2022–2026
▶$500KraisedOct 2026 · 4 investors · BiotechnologyRule 506(b)
▶$500KraisedOct 2026 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Laura E. BenjaminExecutive Officer, Director
- Rebecca WolfeExecutive Officer
- Antonina SimakovaExecutive Officer
- Alan RussellPromoter
- David N. ColaizziDirector
- Barbara S. FoxDirector
- Krzysztof MatyjaszewskiDirector
- Mark A. MurckoDirector
- Offering amount
- $4.5M
- Amount sold
- $500K
- First sale
- Sep 2026
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$1.5MraisedApr 2022 · 8 investors · BiotechnologyRule 506(b)
▶$1.5MraisedApr 2022 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jean PineaultExecutive Officer, Director
- David ColaizziExecutive Officer, Director
- Antonina SimakovaExecutive Officer
- Krzysztof MatyjaszewskiExecutive Officer, Director
- Patrick BaileyExecutive Officer
- Autumn GindlesbergerExecutive Officer
- Offering amount
- $2M
- Amount sold
- $1.5M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Myris Therapeutics do?
- Myris Therapeutics applies polymer chemistry to develop next-generation medicines, with a flagship platform of ultra-high DAR antibody drug conjugates (ADCs). Its technology uses ATRP "growing from" methods to build polymer bottlebrushes that carry payloads, aimed at targeted cancer therapies across oncogenic pathways.
- Who founded Myris Therapeutics?
- Myris Therapeutics was founded by Krzysztof Matyjaszewski in 2022.
- How much funding has Myris Therapeutics raised?
- Myris Therapeutics has disclosed $2M raised across 2 rounds.
- Where is Myris Therapeutics headquartered?
- Myris Therapeutics is headquartered in Sharpsburg, US.